Sarepta price target lowered to $175 from $177 at JPMorgan

JPMorgan lowered the firm’s price target on Sarepta to $175 from $177 and keeps an Overweight rating on the shares. The firm’s base case scenario, a minimum label expansion to the ambulant population, has Sarepta shares valued in the $175-$200 range. In a scenario where the full / majority of the Duchenne muscular dystrophy market is accessible, JPMorgan sees Sarepta shares valued in the $200-$225 range.